Welcome to our dedicated page for IO Biotech news (Ticker: $IOBT), a resource for investors and traders seeking the latest updates and insights on IO Biotech stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IO Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IO Biotech's position in the market.
Rhea-AI Summary
IO Biotech announces that its abstract related to IO102-IO103, the lead investigational therapeutic cancer vaccine candidate, has been accepted for presentation at the 2024 American Society of Clinical Oncology Annual Meeting. The abstract focuses on the Phase 2 trial combining IO102-IO103 with Merck's KEYTRUDA for melanoma and head and neck cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
-
Rhea-AI Summary
IO Biotech appoints Marjan Shamsaei as SVP, Commercial Development, and Portfolio Lead to advance commercialization readiness for IO102-IO103 cancer vaccine candidate in Phase 3 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
-
Rhea-AI Summary
IO Biotech presents new data at AACR Annual Meeting 2024 supporting the use of a dual antigen approach to enhance anti-tumor activity, showcasing the potential of IO102-IO103 in creating an environment for increased anti-tumor effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
Rhea-AI Summary
IO Biotech appoints Faiçal Miyara, Ph.D., as Chief Business Officer to drive global business development activities and strategic partnerships. Dr. Miyara brings over 17 years of experience in the pharmaceutical industry and will focus on advancing the T-Win platform. The company anticipates key milestones in 2024 and 2025, including the Phase 3 interim analysis of their lead therapeutic cancer vaccine, IO102-IO103, and the readout of the primary endpoint of progression-free survival.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.66%
Tags
-
Rhea-AI Summary
IO Biotech (IOBT) presents new nonclinical data at AACR 2024 showcasing the individual contributions of IO102 and IO103 in controlling tumor growth. The abstract highlights the dual antigen vaccine's impact on immune suppression and T effector function, supporting its potential in benefiting patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.63%
Tags
-
Rhea-AI Summary
IO Biotech (IOBT) reported completing enrollment of the pivotal Phase 3 trial of its lead cancer vaccine, IO102-IO103, in combination with KEYTRUDA in patients with advanced melanoma. The company expects an interim analysis for overall response rate in Q3 2024. They also dosed the first patient in a Phase 2 trial of IO102-IO103 in combination with pembrolizumab for solid tumors. IO Biotech ended 2023 with $143.2 million in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.47%
Tags
Rhea-AI Summary
IO Biotech (IOBT) to Present at 44th Annual Cowen Health Care Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
-
News
Rhea-AI Summary
IO Biotech (Nasdaq: IOBT) has announced the dosing of the first patient in its Phase 2 trial studying treatment with IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® in neoadjuvant and adjuvant patients with resectable melanoma or squamous cell carcinoma of the head and neck. The company is conducting a pivotal Phase 3 trial in patients with advanced melanoma, with enrollment completed and an interim analysis planned in 2024. IO Biotech aims to help patients in earlier disease settings with its neoadjuvant/adjuvant trial, IOB-032, involving leading global experts from centers of excellence in the US, Australia, and Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
-
Rhea-AI Summary
IO Biotech (Nasdaq: IOBT) reports completion of enrollment in pivotal Phase 3 trial of IO102-IO103 cancer vaccine in combination with KEYTRUDA®. Encouraging preliminary data from Phase 2 basket trial presented at major medical conferences. Company ended Q3 with $165.5 million in cash, expects to support operations into Q4 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
Rhea-AI Summary
IO Biotech (Nasdaq: IOBT) appoints industry veteran Dr. Helen Collins, MD, to its board of directors, signaling potential advancements in cancer vaccine development. Dr. Collins brings extensive drug development and corporate strategy experience and will serve on the Research and Development Committee. IO Biotech aims to potentially bring its lead cancer vaccine candidate, IO102-IO103, to market for advanced melanoma patients as early as 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
IO Biotech, Inc.
Nasdaq:IOBT
IOBT Rankings
IOBT Stock Data
101.46M
25.98M
2.95%
81.14%
0.1%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
COPENHAGEN
About IOBT
io biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of t cells that are specific for immune inhibitory molecules. io biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting ido and pd-l1 in clinical development and several compounds finalizing preclinical phase. io biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.